PME Investimentos and Seventure invest in LiMM Theraputics

PME Investimentos made the investment via its 200M Co-Investment Fund.

LiMM is a biopharmaceutical company harnessing the molecular crosstalk between neuronal and innate lymphoid cells within peripheral tissues, bridging neural sensing and immunology discoveries to unlock therapeutic offers for patients. The company is the first harnessing the potential of neuronal regulation of Innate Lymphoid Cells (ILC) to tackle medical needs.

Marco Fernandes, CEO of PME Investimentos, said: “It is the first time that a life sciences technology developed at a Portuguese university is able to attract international venture capital as specialized as Seventure Partners. The 200M Fund is honored to support the entrepreneurs and scientific researchers from the Champalimaud Foundation, Henrique Veiga Fernandes and David Braga Malta and the future development of LiMM.”

The 200M Co-Investment Fund, managed by PME Investimentos – Sociedade de Investimento, is a matching fund that aims to foster co-investment in high growth starts ups in Portugal, with national or international private co-investors.

Seventure Partners has a key focus on venture capital with €750 million under management. Headquartered in Paris, Seventure have completed more than 150 exits, and 25 IPOs. 

Seventure’s CEO is Isabelle de Cremoux.

Portuguese law firm Abreu Advogados advised PME Investimentos on the deal. The Abreu Advogados team was led by partner Ana Sofia Batista, and included professional partner Rodrigo Formigal and senior associate André Modesto Pinheiro.